Asthma

Vapotherm's Asthma Therapy More Effective Than Standard Oxygen Therapy In Kids

Amgen's Tezspire Reduces Annualized Exacerbation Rate In Severe Asthma Patients

CHMP Backs Sanofi-Regeneron's Dupixent For Asthma Patients Aged 6 - 11 Years With Type 2 Inflammation

Amgen's Tezspire Reduces Annualized Exacerbation Rate In Severe Asthma Patients

CHMP Backs Sanofi-Regeneron's Dupixent For Asthma Patients Aged 6 - 11 Years With Type 2 Inflammation

4D Pharma's Asthma Candidate Shows Positive Trends In Multiple Secondary Endpoints Of Efficacy

Equillium To Reassess Potential For Its Asthma Trials

4D Pharma's Asthma Candidate Shows Positive Trends In Multiple Secondary Endpoints Of Efficacy

Equillium To Reassess Potential For Its Asthma Trials

AstraZeneca - Amgen's Tezspire Biologic Scores FDA Approval For Severe Asthma

Why Are Theravance Bio Shares Plummeting Premarket Today?

Asthma Recent News

AstraZeneca's Two Asthma Trials Meet Primary Endpoints

Amgen, AstraZeneca Tout Additional Data From Asthma Trial With Tezepelumab

Amgen - AstraZeneca's Asthma Candidate Under Priority Review With FDA

New Five-Year Data Shows Durable Efficacy Of AstraZeneca's Fasenra For Asthma Treatment

Sanofi-Regeneron Tout New Data For Dupixent From Pediatric Asthma Trial

Sanofi/Regneron's Dupixent Application For Asthma In Children Accepted For FDA Review

The FDA has accepted for review the supplemental marketing application seeking approv

Regeneron's Single-Dose REGN1908-1909 Shows Rapid, Durable Benefit In Cat-Allergic Asthma Patients

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) has

AstraZeneca/Amgen's Tezepelumab Reduces Asthma Exacerbations, Phase 3 Trial Shows

Sanofi, Regeneron Report Positive Phase 3 Results For Asthma Drug Dupixent's Use In Children

Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN)

Amid Few Catalysts, Jefferies Downgrades AstraZeneca